INTRODUCTION
Prolific angiogenesis driven principally by vascular endothelial growth factor (VEGF) is a hallmark of glioblastoma, the most common primary malignant brain tumor among adults. 1, 2 The outcome of patients with glioblastoma remains poor, and effective therapies after progression on current standard therapy with radiation and temozolomide chemotherapy remain elusive. Given the histopathologic prominence of angiogenesis associated with glioblastoma, substantial effort has been focused on targeting VEGF as a therapeutic strategy. Randomized phase 3 clinical trials demonstrated that bevacizumab, a humanized monoclonal antibody that blocks VEGF signaling, significantly prolongs progression-free survival (PFS) when combined with lomustine for patients with recurrent glioblastoma 3 and combined with radiation plus temozolomide for newly diagnosed patients. 4, 5 Unfortunately, those studies in unselected patients failed to demonstrate an improvement in overall survival (OS), although 30% to 50% of control patients on the studies received bevacizumab at progression, and the impact of cross-over on survival remains unknown.
A potential contributing factor to the failure of VEGF blockade to improve survival may be the recruitment and activity of additional proangiogenic factors to support glioblastoma growth. [6] [7] [8] Angiopoietins (ANGs) are critical mediators of the angiogenic switch, which is associated with tumor progression through interaction with the transmembrane tyrosine protein kinase angiopoietin (Tie2) receptor expressed by tumor endothelial cells, 9 and ANGs also appear to contribute to glioblastoma growth. ANG-1 and ANG-2 as well as the TIE-2 receptor are expressed by glial tumors and associated vasculature. 10, 11 In preclinical studies, the antitumor benefit of ANG/TIE-2 blockade using antibodies 12, 13 or multikinase inhibitors 14, 15 was enhanced when combined with VEGF inhibition in several orthotopic glioblastoma models. [12] [13] [14] [15] Trebananib (AMG386) is an investigational anti-ANG peptibody composed of an ANG binding peptide fused to the Fc region of an antibody that inhibits the interaction of both ANG-1 and ANG-2 ligands with the TIE-2 receptor. 16, 17 Phase 1 studies demonstrated an acceptable toxicity profile when administered as single agent 18, 19 and in combination with chemotherapy for patients with advanced solid tumors. 20 Early clinical trials demonstrated encouraging antitumor activity of trebananib in patients with various types of solid tumors. [21] [22] [23] [24] In the current phase 2 study, we evaluated intravenous trebananib (30 mg/kg weekly) administered as single agent and in combination with intravenous bevacizumab (10 mg/kg biweekly) for patients with recurrent glioblastoma. Circulating biomarkers of angiogenesis and inflammation were evaluated to explore potential biomarkers that could be used to enable rational patient selection in future studies.
MATERIALS AND METHODS

Participants
Eligible patients were at least age 18 years, were in first or second relapse of histologically confirmed glioblastoma after standard therapy (maximum feasible resection or biopsy, radiation, and temozolomide), and had a Karnofsky performance status of at least 70 as well as adequate hematologic, renal, and hepatic function. Patients who had previously received radiation and temozolomide for lower grade glioma were included upon a diagnosis of transformed glioblastoma. Eligibility criteria excluded: prior receipt of VEGF/VEGF receptor (VEGFR) or ANG-targeting agents; grade > 1 hemorrhage on baseline magnetic resonance imaging; residual grade 2 chemotherapy or radiation-related toxicities (except alopecia and hematologic toxicity); and salvage surgery within 4 weeks, radiation within 3 months, and chemotherapy within 4 weeks (6 weeks for nitrosoureas) of enrollment. Pregnant or lactating patients and those with active infection, ongoing use of warfarin, arterial or deep venous thromboembolism within 12 months, or inadequately controlled hypertension also were excluded.
Study Design and Treatment
This was a phase 2, multicenter, open-label, 2-cohort study of intravenous trebananib (30 mg/kg weekly) among patients with recurrent, bevacizumab-naive glioblastoma. The trebananib dose was selected based on prior phase 1 data demonstrating the lack of dose-limiting toxicity for weekly doses up to 30 mg/kg 19 and several studies demonstrating improved outcomes with higher doses. 22, [25] [26] [27] Patients in cohort A were accrued initially and received trebananib monotherapy. After the completion of cohort A accrual, patients were enrolled on cohort B and received trebananib plus bevacizumab (10 mg/kg biweekly). Cohort B included a lead-in to assess the safety of combination therapy, because these 2 agents had never been combined at the dose levels specified. Each cycle was 28 days and required an absolute neutrophil count 1000/ lL, platelet count 100,000/lL, serum creatinine level 1.5 times the upper limit of normal, aspartate aminotransferase and bilirubin levels2.5 time the upper limit of normal, urine protein 30 mg/dL, and resolution of any grade 3 toxicity at least possibly related to study therapy to grade 1 or to the pretreatment baseline level. Supportive medications, including antiemetics, antidiarrheal agents, hematopoietic growth factors, and lowmolecular-weight heparin, were permitted for patients on study; but warfarin, herbal preparations, and other cancer therapies were not permitted. No dose reductions were included for bevacizumab, but the study protocol guided trebananib dose modification for toxicity to 15 or 10 mg/ kg weekly and provided criteria for permanent discontinuation of either study agent. For patients in cohort B, if 1 study agent was discontinued for toxicity, then the other agent was allowed to continue provided it was unrelated to the toxicity. Treatment continued until tumor progression, unacceptable toxicity, noncompliance, or withdrawal of consent.
Toxicity was monitored and graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). Safety assessments included weekly physical examination, vital signs, and routine hematology, blood chemistry, and urinalysis during study therapy. Response was assessed by the treating investigator using Radiologic Assessment in NeuroOncology criteria every 8 weeks.
The study was compliant with the Declaration of Helsinki and guidelines on Good Clinical Practice. Ethics approval was obtained at all participating centers, and all patients provided informed consent before participation. The study protocol is available at clinicaltrials.gov (National Clinical Trials identifier NCT01609790).
Circulating Biomarker Analyses
Plasma biomarkers were evaluated in both cohorts at baseline, on days 2 and 8 of cycle 1, on day 1 of cycles 2 and 3, and at the end of treatment. Plasma was separated from fresh blood samples, and all samples were aliquoted and frozen. Analyses were carried out for biomarkers of angiogenesis and inflammation molecules at the end of the study, including: VEGF, placental growth factor (PlGF), VEGF C precursor (VEGF-C), VEGF-D, soluble (s)VEGFR1, basic fibroblast growth factor (bFGF), soluble Tie-2 (sTie-2), interferon c, interleukin 1b (IL-1b), IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and transforming growth factor a using multiplex arrays from Meso-Scale Discovery (Gaithersburg, MD); and ANG-1 and ANG-2 using enzyme-linked immunosorbent assay plates from R&D Systems (Minneapolis, MN). All samples were run in duplicate in the Certified Laboratory Improvement Amendments-certified core of the Steele Laboratories at Massachusetts General Hospital.
Statistical Analysis
The primary endpoint for each cohort was PFS after 6 months (PFS-6) according to Radiologic Assessment in Neuro-Oncology criteria. 28 Secondary endpoints were determination of the objective response rate (ORR), OS, and overall safety and tolerability. Exploratory endpoints included evaluation of the association of pretreatment and post-treatment circulating biomarkers with outcome. A 2-stage design was used for cohort A. If more than 1 of the first 14 patients treated on cohort A achieved a radiographic response, then accrual to cohort A would continue to a total of 34 patients. If 1 or fewer of the first 14 achieved an ORR, then accrual to cohort A would stop, because single-agent trebananib would be predicted to be less active than bevacizumab. Accrual to cohort B included an initial safety lead-in of 6 patients with de-escalation of trebananib if more than 1 of the first 6 patients experienced protocol-defined dose-limiting toxicity during cycle 1.
With the accrual of 34 patients per cohort, study therapy was to be considered promising if 19 or more patients were progression-free at 6 months. Patients who left the study sooner without documented progression or as a result of death were conservatively treated as events for primary endpoint analysis. The design discriminated between true PFS-6 42% and >65%, with Type I and II error rates of 8.1% and 9.9%, respectively. A PFS-6 rate of 42% was chosen based on phase 2 data for bevacizumab plus irinotecan in the same target population. 29 The primary analyses were performed for the intent-totreat population. Per protocol analyses were performed with patients who completed at least 50% of the first cycle of study therapy. Three additional patients were allowed to enroll on cohort B to account for possible study dropout.
Time-to-event analyses, including PFS and OS, were calculated using the Kaplan-Meier method. The logrank test was used for comparisons between groups. The time to progression was defined as the time from treatment start to disease progression or death within 28 days of treatment end. Patients who did not progress or die within 28 days of treatment end were censored at the date of treatment end or last assessment. OS was defined as the time from treatment start until death from any cause.
The percent change in blood biomarker levels from before, during, and after treatment was summarized using descriptive statistics, and differences between time points were evaluated using the signed-rank test. Correlations between circulating biomarker levels at baseline and on treatment and PFS or OS were analyzed by fitting a univariate Cox proportional hazard model, and the results are presented with hazard ratios (HRs), which represent the increase or decrease in the chance of progression or death per percentage increase or for 2-fold changes in the biomarker level tested. 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Angiopoietin
RESULTS
Study Patients
Between November 2012 and January 2015, 48 bevacizumab-naive patients were enrolled. Summary demographics and baseline patient characteristics were comparable for both cohorts (Table 1) . Eleven patients were accrued to cohort A, including 1 who withdrew consent after a single dose of study therapy. Accrual to cohort A was discontinued early, because each of the first 10 evaluable patients progressed within 2 months of initiating study therapy. For cohort B, none of the first 6 patients enrolled during the safety lead-in experienced dose-limiting toxicity; therefore, accrual was completed, including 34 planned patients plus 3 additional patients to account for potential drop-out. All patients have discontinued study therapy. Forty-seven patients have died, and 1 patient remains in active follow-up.
Safety
Adverse events at least possibly related to study therapy are summarized by grade and treatment cohort in Table 2 . In general, treatment was well tolerated, although low-grade toxicities were common. Toxicity with trebananib monotherapy (cohort A) included uncommon grade 1 and 2 events, although duration of therapy was limited because all patients progressed within 2 months. For patients in cohort B, the addition of trebananib to bevacizumab did not appear to worsen the frequency or severity of classspecific adverse events for VEGF inhibitors. [3] [4] [5] Specifically, 38% of cohort B participants developed grade 3 or 4 hypertension, whereas 6% developed grade 3 thrombosis. Proteinuria was limited to grade 1 and 2 and affected 6% of patients, and no episodes of hemorrhage other than grade 1 epistaxis (9%) occurred. No patients required dose modification of trebananib. One patient who was treated on cohort B required discontinuation of study therapy because of toxicity (grade 3 peripheral edema). There were no deaths on study attributed to study therapy.
Efficacy
Efficacy outcomes for the intent-to-treat population are summarized in Figure 1 . Single-agent trebananib at 30 mg/ kg weekly (cohort A) was inactive, and all patients developed progressive disease within 2 months of study entry. In cohort A, the median PFS was 0.7 months (95% confidence interval [CI], 0.17-1.2 months), and the median OS was 11.4 months (95% CI, 4.6-18.5 months).
In cohort B, 27% of patients achieved an objective response, including 10 patients who had a partial response, but none achieved a complete response. The median duration of objective response was 3.5 months (range, 1.8-15.9 months). In addition, 14 patients (41%) achieved stable disease. The median PFS was 3.6 months (95% CI, 1.9-5.5 months). The PFS-6 rate for cohort B was 24.3% (95% CI, 12.1%-38.8%). The median OS was 9.5 months (95% CI, 7.5-14.7 months), and the OS-12 rate was 37.8% (95% CI, 22.6%-53.0%). There was no association between historic prognostic factors and outcome (Table 3) .
Circulating Biomarker Analyses
AMG386 treatment alone rapidly and significantly increased plasma ANG-1, ANG-2, PlGF, and IL-10 levels and decreased plasma bFGF levels at day 2 and increased plasma ANG-2 and IL-10 at day 8 (Supporting Table 1 ; see online supporting information). The other cytokines measured did not exhibit any significant changes after treatment, and there were insufficient samples collected at later time-points because of rapid disease progression in cohort A. Combined treatment with AMG386 and bevacizumab induced significant and sustained increases in plasma levels of ANG-1, ANG-2, PlGF, VEGF-D, and IL-8 and a decrease in plasma levels of free VEGF (at all time points) ( Table 4 ). There was a transient decrease in plasma sVEGFR1 (day 2), and an initial increase (at days 2 and 8) was followed by a decrease in plasma sTIE-2 (at cycle 3, day 1 and off treatment) ( Table 4) .
In an exploratory analysis of correlations between baseline biomarkers and outcome, we observed that high plasma VEGF was associated with poor PFS and OS, and high plasma IL-8 was associated with shorter OS (P < .05) ( Table 5, Supporting Table 2 ; see online supporting information). These associations were not observed in the patients who received AMG386 monotherapy (data not shown). For changes after combination treatment, PFS was directly associated with plasma VEGF (cycle 2, day 1 and cycle 3, day 1) and was associated inversely with plasma IL-8 (day 2) ( Table 5) ; and OS was directly associated with plasma VEGF (cycle 2 day 1) and was inversely associated with plasma IL-8 (day 2) ( Table 5) .
DISCUSSION
Glioblastoma is a highly angiogenic cancer in which vascular proliferation is included as a requisite histopathologic finding. Inhibition of VEGF, the key driver of tumor angiogenesis, has resulted in meaningful PFS improvement but has not translated into an OS benefit for patients with either recurrent or newly diagnosed glioblastoma. [3] [4] [5] Failure to translate an initial therapeutic benefit into a durable 1 suggests that upregulation of compensatory mechanisms can overcome the therapeutic impact rendered by VEGF inhibition. Upregulation of alternative proangiogenic factors, including ANG-2, as a compensatory response has been demonstrated after VEGF inhibitor therapy among patients with glioblastoma. 30 ANGs are known to contribute significantly to tumor angiogenesis. Preclinical studies demonstrate that VEGF blockade leads to increased ANG-2 expression in glioblastoma tumor vasculature, suggesting that ANG activity may contribute to tumor resistance to VEGF inhibition. 15 Therefore, dual blockade of ANGs and VEGF signaling as a complementary strategy to undermine tumor angiogenesis provides the rationale for the current phase 2 study of trebananib with and without bevacizumab for patients with recurrent glioblastoma.
Preclinical data validate the concept that inhibition of ANGs may enhance the antitumor benefit of VEGF blockade. It has been demonstrated that ANG-2 blockade using 2 different monoclonal antibodies significantly prolongs survival in orthotopic glioblastoma models compared with VEGF blockade 12, 13 and prolongs survival when combined with VEGF blockade compared with VEGF blockade alone. 14, 15 In contrast, downregulation of ANG-1 or overexpression of ANG-2 decreased both vessel normalization and therapeutic benefit associated with VEGF blockade. 31, 32 In the current phase 2 study, trebananib, a dual ANG-1/ANG-2 inhibitor, was evaluated as a single agent and in combination with bevacizumab for patients with bevacizumab-naive, recurrent glioblastoma. Despite the rationale and supportive preclinical data using the kinase inhibitors altiratinib or trebananib, the activity of ANG-1/ANG2 blockade observed in this study was disappointing. Among the patients who received treatment with single-agent trebananib, there was no sign of efficacy, because all 10 patients exhibited progressive disease within 2 months. Furthermore, when combined with bevacizumab, trebananib did not appear to enhance the therapeutic benefit of bevacizumab. Specifically, among patients who received treatment with trebananib plus bevacizumab (cohort B), the primary endpoint of PFS-6 was not met. Furthermore, the PFS-6 rate, the ORR, and the median PFS and OS were comparable to historic benchmarks reported for bevacizumab among patients with recurrent glioblastoma. 29, 33 Finally, the percentage of patients who had prolonged survival (ie, those at the tail of the KaplanMeier OS curve) does not appear to be increased relative to that achieved with bevacizumab in this setting. 
Original Article
Although our study lacked a contemporaneous bevacizumab monotherapy arm, our results indicate that trebananib does not augment the clinical benefit of bevacizumab among patients with bevacizumab-naive, recurrent glioblastoma. It is possible that the benefit of blocking ANG-2 signaling may be compromised by blocking ANG-1 signaling, because these 2 ligands exert opposite effects in a context-dependent manner. 31, 32 In our current study, trebananib was associated with modest toxicity, including grade 1 and 2 extremity edema in 9% of patients. Trebananib did not increase the rate or severity of adverse events previously associated with bevacizumab, such as fatigue, hypertension, proteinuria, and thromboembolic events; and it is noteworthy that there were no episodes of serious hemorrhage.
The disappointing efficacy results from our study are consistent with a lack of meaningful antitumor benefit observed with trebananib across several cancer types to date. Trebananib was ineffective when administered as a single agent for endometrial cancer 34 and angiosarcoma, 35 and it also did not improve outcome when combined with chemotherapy for metastatic colorectal carcinoma 36 or metastatic esophageal cancer 37 or when combined with sorafenib for patients with metastatic clear cell kidney cancer. 38 Among patients with metastatic ovarian cancer, a large, placebo-controlled, double-blind phase 3 study demonstrated that the addition of trebananib to paclitaxel improved PFS but not OS. 39, 40 Previous studies suggested that the antitumor efficacy of trebananib may be dose-related. Increased trebananib dose exposure was associated with a better outcome among patients with recurrent ovarian cancer, 22, 25 whereas doses 10 mg/kg failed to improve outcomes for patients with metastatic breast cancer. 26 Among patients with metastatic renal cell cancer, receipt of 15 mg/kg was associated with improved PFS and OS compared with 10 mg/kg when added to sunitinib. 27 Nonetheless, it is unlikely that dose was a contributing factor to the lack of therapeutic benefit observed in the current study, because trebananib was dosed weekly at 30 mg/kg, and fluid retention-a recognized side effect of ANG inhibition 41 -was observed among treated patients. It is interesting to note that a recently completed study in which patients with recurrent glioblastoma were randomized to receive either trebananib (dosed at 15 mg/kg) plus bevacizumab or bevacizumab alone demonstrated comparable outcomes between the 2 treatment cohorts. 42 An analysis of circulating biomarkers indicated that trebananib alone increased the concentration of ANG-1 (transiently) and ANG-2 (at both days 2 and 8). This increase was significant and was detectable at all time points measured in the patients who received trebananib plus bevacizumab. These data indicate that trebananib may increase the blood circulation time of ANG-1 and particularly of ANG-2. This phenomenon has been observed with bevacizumab (ie, an increase in circulating VEGF bound to the antibody). Our findings are consistent with those of others reporting that serum ANG-2 levels remain unchanged in patients with glioblastoma after bevacizumab therapy despite a 66% decrease in endothelial cells, which are the cellular source of ANG-2 in glioblastoma. 15 The kinetics of free ANG-1 and ANG-2 after trebananib are unknown.
Plasma concentrations of free VEGF were significantly decreased in the combination group and were unchanged in the Trebananib-alone group, consistent with its blockade by bevacizumab. In contrast, plasma PlGF was increased after treatment in both cohorts. Increased plasma PlGF has been identified previously as a pharmacodynamic biomarker of anti-VEGF therapy 30 ; however, it is interesting to note that, in the current study, we also detected an increase after trebananib monotherapy. It is also noteworthy that greater decreases in free VEGF as well as a rapid increase in plasma IL-8 were associated with worse PFS and OS, consistent with correlations reported in patients with glioblastoma who received treatment with cediranib. 43, 44 Treatment with trebananib plus bevacizumab increased plasma levels of VEGF-D and IL-8 at all time points. Increases in IL-8 have not been consistently observed with anti-VEGF therapies.
In summary, our biomarker studies demonstrated changes in circulating levels of the targets of trebananib, ANG-1 and ANG-2, as well as PlGF. These changes were confirmed in the combination therapy cohort and, together, suggest target modulation by these interventions. The limitations of this study are related to the small sample size and the lack of signals of synergy between trebananib and bevacizumab anti-VEGF therapy for recurrent glioblastoma. In addition, imaging studies to assess a pharmacodynamic impact on tumor vasculature were not included in this study, so the significance of changes in circulating biomarkers relative to their impact on target tumor vasculature is not known. Nevertheless, the associations between plasma free VEGF and IL-8 levels and survival outcomes are potentially relevant, and their role as predictive or prognostic biomarkers should be further investigated in future studies of bevacizumab, either alone or in combination with other agents in recurrent glioblastoma.
In conclusion, the inhibition of ANG-1/ANG-2 with weekly administration of trebananib at 30 mg/kg failed to improve outcomes when received as single-agent therapy and in combination with bevacizumab among patients with recurrent glioblastoma despite evidence of impact on circulating angiogenic cofactors. It is noteworthy that recent studies evaluating ANG inhibitors suggest that ANG-2 may be a more important therapeutic target for tumor angiogenesis than ANG-1. 12, 13, 15, 31, 45 In addition, ANG-2 has also recently been described as an important biomarker and target for immune checkpoint therapy. 46 Although further evaluation of trebananib is not warranted for glioblastoma, additional studies of agents capable of specifically targeting ANG-2 may prove of value, because blocking ANG-1 may abrogate the benefits of blocking ANG-2.
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